Hydroxychloroquine and the Ethical Pitfalls of Private Science
The retraction of three papers on treating COVID-19 with hydroxychloroquine reflect a crisis in the scientific community: how to handle data from private companies. What reforms are necessary to avoid such data-based scandals in the future?